Ekkehard von Abel

Statistics

Publications

Citations

233

H-Index

Active since

2014

Affiliations

Universitätsklinikum Erlangen(Current)

Ludwig-Maximilians-Universität München

University Hospital Ulm

Breast Center

Ekkehard von Abel is an author at Universitätsklinikum Erlangen specializing in medicine, human epidermal growth factor receptor 2-targeted therapy, and oncology.

Publications per year

2014–2023

Publications

Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44–GeparQuinto)

Gϋnter von Minckwitz, Gϋnter von Minckwitz, Sibylle Loibl et al. · Annals of Oncology · 2014 · 140 citations

Medicine, Oncology, Pharmacology +15

The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial

Bernadette Jaeger, Jörg Neugebauer, U Andergassen et al. · PLoS ONE · 2017 · 52 citations · Full text

Medicine, Cancer Biology, Oncology +16

Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial

Nadia Harbeck, Peter A. Fasching, Rachel Wuerstlein et al. · Annals of Oncology · 2023 · 41 citations · Full text

Medicine, Oncology, Pharmacology +17

1–3 of 3